enGene Therapeutics (ENGN) Insider Grossman Buys 231,000 Shares

William Grossman, the Interim Chief Medical Officer of enGene Therapeutics Inc. (NasdaqCM:ENGN), recently acquired 231,000 shares of the company. This insider transaction took place on June 16, 2026, and reflects Grossman's continued involvement with the company, though the purchase price was not disclosed.

enGene Therapeutics Inc. Stock Down 8.9%

Shares of enGene Therapeutics traded around $1.75 recently. The company has a market capitalization of approximately $117.2 million. enGene is not currently profitable, as indicated by its forward P/E ratio of -1.04. The stock has experienced a wide 52-week price range, with a low of $1.40 and a high of $12.25. Its 50-day moving average stands at $4.33, while the 200-day moving average is $7.13. Financially, the company maintains a current ratio of 12.57 and a quick ratio of 12.07, with a debt-to-equity ratio of 13.07.

About enGene Therapeutics

enGene Therapeutics Inc. is a biotechnology company based in Montreal, Canada. It focuses on developing genetic medicines, particularly for patients suffering from bladder cancer. The company's leading product candidate is detalimogene voraplasmid, which is aimed at treating non-muscle invasive bladder cancer. enGene is also advancing a project known as LEGEND, currently in Phase 2 trials. The company, led by CEO Ronald H. W. Cooper, was formerly known as enGene Holdings Inc. before its name change in April 2026.

Bottom Line

William Grossman's significant share purchase underscores his commitment to enGene Therapeutics. As a clinical-stage biotech company, enGene is working on innovative treatments for bladder cancer, which could be promising for future growth. Investors often keep a close eye on insider transactions, as they can signal confidence in a company's prospects. However, it's important to remember that such transactions are just one piece of the broader investment puzzle.